Shots:
Foresight & Allogene have expanded their strategic collaboration to develop minimal residual disease (MRD) assay as companion diagnostic to identify candidates for Allogene's ALPHA3 trial assessing cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL) pts
As per the collaboration, Allogene & Foresight will develop Foresight's MRD assay in the EU, UK, Canada &…
